Portola Pharma (PTLA) Misses Q4 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Portola Pharmaceuticals (PTLA) PT Raised to $50 at Citi
March 4, 2019 6:58 AM ESTCiti analyst Yigal Nochomovitz raised the price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $50.00 (from $49.00) while maintaining a Buy rating as the company launches Andexxa. Nochomovitz is being executed well under the new CEOs leadership and should be owned as path to Andexxa growth is... More
